Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma

被引：14

作者：

Bain, C

Merrouche, Y

Puisieux, I

Blay, JY

Negrier, S

Bonadona, V

Lasset, C

Lanier, F

Duc, A

Gebuhrer, L

Philip, T

Favrot, MC

机构：

[1] CTR LEON BERARD,DEPT TUMOR BIOL,F-69008 LYON,FRANCE

[2] CTR LEON BERARD,DEPT MED ONCOL,F-69008 LYON,FRANCE

[3] CTR LEON BERARD,DEPT BIOSTAT,F-69008 LYON,FRANCE

[4] CTR TRANSFUS SANGUINE,HISTOCOMPATIBIL LAB,F-69007 LYON,FRANCE

来源：

BRITISH JOURNAL OF CANCER | 1997年 / 75卷 / 02期

关键词：

HLA; renal cell carcinoma; interleukin; 2; immunotherapy;

D O I：

10.1038/bjc.1997.46

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

HLA phenotypes were characterized for 79 patients with metastatic renal cell carcinoma treated with interleukin 2 (IL-2). HLA-A32 was associated with a clinical response (P=0.025). The frequency of HLA-AS and/or A32 was higher among responders than non-responders (P=0.008). Thus, these results suggest that, in vivo, IL-2 may enhance cellular-mediated immunity against a tumour antigen and that some MHC molecules are more efficient than others for endogenous tumour antigen presentation.

引用

页码：283 / 286

页数：4

共 22 条

[1] HOME THERAPY WITH RECOMBINANT INTERLEUKIN-2 AND INTERFERON-ALPHA-2B IN ADVANCED HUMAN MALIGNANCIES [J].

ATZPODIEN, J ;

KORFER, A ;

FRANKS, CR ;

POLIWODA, H ;

KIRCHNER, H .

LANCET, 1990, 335 (8704) :1509-1512

[2]

Bain C, 1996, INT J CANCER, V67, P769

[3] CELLULAR IMMUNE-RESPONSE TO HUMAN RENAL-CELL CARCINOMAS - DEFINITION OF A COMMON ANTIGEN RECOGNIZED BY HLA-A2-RESTRICTED CYTOTOXIC T-LYMPHOCYTE (CTL) CLONES [J].

BERNHARD, H ;

KARBACH, J ;

WOLFEL, T ;

BUSCH, P ;

STORKEL, S ;

STOCKLE, M ;

WOLFEL, C ;

SELIGER, B ;

HUBER, C ;

ZUMBUSCHENFELDE, KHM ;

KNUTH, A .

INTERNATIONAL JOURNAL OF CANCER, 1994, 59 (06) :837-842

[4]

BLAY JY, 1992, CANCER RES, V52, P3317

[5] PROLONGED SURVIVAL IN BRONCHOGENIC CARCINOMA ASSOCIATED WITH HL-A ANTIGENS W-19 AND HL-A5 - PRELIMINARY REPORT [J].

DELLON, AL ;

ROGENTINE, GN ;

CHRETIEN, PB .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1975, 54 (06) :1283-1286

[6]

FALK J, 1971, LANCET, P1118

[7]

FINKE JH, 1993, CANCER RES, V53, P5613

[8]

KANTOR AF, 1983, CANCER RES, V43, P2330

[9]

LILLY F, 1964, LANCET, V2, P1207

[10]

MARINCOLA FM, 1996, J IMMUNOTHER, V18, P242

← 1 2 3 →